Biotech Business - August 2, 2021
Hansa Biopharma announces reimbursement in the Netherlands of Idefirix
Hansa Biopharma has announced that its treatment Idefirix is, as of August 1, reimbursable and available for use in the Netherlands. Idefirix is the first and only treatment approved for use in the European Union for desensitization of highly sensitized patients prior to kidney transplantation, allowing them to be considered for a life-altering kidney transplantation […]
New Market - June 23, 2021
AstraZeneca’s Orpathys approved in China
AstraZeneca and HUTCHMED’s Orpathys has been granted conditional approval in China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. This approval follows a priority review designation by the Center for Drug Evaluation of China’s National […]
New Market - February 4, 2021
Elypta launches research service for glycosaminoglycan profiling
Elypta has announced the launch of the first standardized service for full spectrum glycosaminoglycan quantification for researchers. Elypta is also launching a sponsorship program to support more academic research in the field, prioritizing fundamental, pre-clinical, and clinical questions about how glycosaminoglycans relate to cancer. Glycosaminoglycan profiling Glycosaminoglycans (GAGs) are polysaccharides with relevance across a wide […]
New Market - January 19, 2021
Oasmia secures IP rights in Australia and Brazil
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17, a drug-delivery system currently used with paclitaxel and other cancer drugs. The patent is important for Oasmia as it expands the territories for exclusivity of the key technology XR‑17 used in our lead product Apealea (paclitaxel micellar), which is being launched in […]
In a new job - September 7, 2020
Nanoform expands its global commercial team
Nanoform has appointed Eric Peter and Sergie Letser to drive the company’s business development in the US. The expansion to Nanoform’s commercial team will give the company a strengthened presence in the US market and enable a continued rate of rapid global growth, it states. Eric Peter Eric Peter will utilize his business development and […]
New Market - July 28, 2020
Rybelsus approved in Japan for the treatment of type 2 diabetes
Novo Nordisk has announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus (oral semaglutide), the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) in a tablet, for the treatment of adults with type 2 diabetes. The approval of Rybelsus in Japan is based on results from the PIONEER clinical […]
